Kepler starts Galderma with 'buy' on high impact product launches

Galderma AG

06/06/2025 12:01

** Kepler Cheuvreux begins coverage of Swiss pharmaceutical company Galderma GALD.S with "buy", citing rising margins and launches of Nemluvio and Reflydess

** Injectable Nemluvio is set to transform the therapeutic franchise in terms of both sales and profitability while skincare product Reflydess strengthens the aesthetics portfolio with longer duration and attractive economics, Kepler says

** Galderma reported on Friday that long-term data on Nemluvio demonstrates its sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis for up to two years and a favourable safety profile

** Kepler says the company combines the scientific upside of biopharma with the pricing power of capital consumer health, leading to less exposure in both fields

** Among the 12 analysts that cover Galderma, the breakdown of recommendations are 10 "strong buy" or "buy" and two "hold" - LSEG data

 (Reporting by Cian Muenster)

 ((Cian.muenster@thomsonreuters.com))